59.22
Praxis Precision Medicines Inc Borsa (PRAX) Ultime notizie
What analysts say about Praxis Precision Medicines Inc. stock outlookFree Market Volatility Navigation Tips - jammulinksnews.com
Why Praxis Precision Medicines Inc. stock attracts strong analyst attentionTriple Digit Return Forecasts - Newser
Will Praxis Precision Medicines Inc. stock benefit from AI tech trendsPhenomenal capital gains - jammulinksnews.com
Praxis Precision Medicines Inc. Stock Analysis and ForecastTremendous return on equity - Autocar Professional
Is Praxis Precision Medicines Inc. a good long term investmentExceptional profit potential - PrintWeekIndia
Praxis Precision Medicines, Inc. (NASDAQ:PRAX) Receives Consensus Rating of “Moderate Buy” from Analysts - Defense World
What analysts say about Praxis Precision Medicines Inc. stockBreakthrough capital growth - jammulinksnews.com
What drives Praxis Precision Medicines Inc. stock priceConsistent triple-digit returns - jammulinksnews.com
Major Depressive Disorder Clinical Trials, Companies, - openPR.com
What makes Praxis Precision Medicines Inc. stock price move sharplyFree Stock Selection - Newser
Does Praxis Precision Medicines Inc. stock pay reliable dividendsShort Squeeze Radar - Newser
Praxis Precision Medicines’ (PRAX) Buy Rating Reiterated at HC Wainwright - Defense World
(PRAX) Trading Report - news.stocktradersdaily.com
Here's Why We're Not Too Worried About Praxis Precision Medicines' (NASDAQ:PRAX) Cash Burn Situation - 富途牛牛
Praxis Precision Medicines stock gets BTD for relutrigine, H.C. Wainwright maintains Buy - Investing.com Nigeria
Praxis Precision Medicines stock gets BTD for relutrigine, H.C. Wainwright maintains Buy By Investing.com - Investing.com South Africa
PRAX: HC Wainwright & Co. Reiterates Buy Rating with $105 Target - GuruFocus
Praxis Precision gets FDA breakthrough therapy status for Relutrigine - Seeking Alpha
FDA grants breakthrough therapy designation to Praxis’ relutrigine for pediatric epilepsy - Investing.com Canada
Q1 Earnings Forecast for PRAX Issued By HC Wainwright - Defense World
Praxis Precision Medicines and the Breakthrough Potential of Relutrigine in Rare Epilepsy Therapies: Strategic and Financial Implications of FDA Breakthrough Therapy Designation - AInvest
Praxis Says FDA Grants Breakthrough Therapy Designation To Relutrigine For Rare Pediatric Epilepsies - Nasdaq
FDA grants breakthrough therapy status to Praxis’s relutrigine By Investing.com - Investing.com Canada
FDA grants breakthrough therapy status to Praxis’s relutrigine - Investing.com Australia
Praxis Precision Medicines Gains FDA Breakthrough Designation - TipRanks
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):